| Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL | Chemotherapy | Drug | Race | TIMEPOINT | Tamoxyfen | Taxane |
|---|---|---|---|---|---|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 1949 | Peak area | Case | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 2039 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 2305 | Peak area | Control | Y | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 2660 | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3199 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3234 | Peak area | Control | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3310 | Peak area | Control | Y | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3769 | Peak area | Control | N | Exemestane | Black | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3844 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3885 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3983 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 3997 | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 4029 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 4047 | Peak area | Control | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 4108 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 4182 | Peak area | Control | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 4800 | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 4883 | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 5182 | Peak area | Case | N | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 5723 | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 5905 | Peak area | Control | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 5913 | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 6202 | Peak area | Control | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 6320 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 6574 | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 6648 | Peak area | Case | N | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 6885 | Peak area | Case | N | Exemestane | Black | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 7275 | Peak area | Case | N | Letrozole | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 7625 | Peak area | Case | N | Letrozole | Black | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 7727 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 8211 | Peak area | Case | N | Letrozole | Black | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 8358 | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 8429 | Peak area | Control | N | Letrozole | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 9182 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 9311 | Peak area | Control | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 10690 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | 11156 | Peak area | Case | N | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Exemestane | Black | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | N | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Letrozole | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Letrozole | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Letrozole | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | N | Letrozole | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | ALANINE (CAS# 56-41-7); (M+H)+ | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|